PHARMACOKINETICS
Although Luliconazole is applied topically, pharmacokinetic studies have demonstrated that there is some systemic absorption. In clinical trials, plasma concentrations of luliconazole on 15 day were measurable in all tinea pedis and tine cruris subjects and fluctuated little during the 24-hour interval.
Protein binding: >99%

PHARMACODYNAMIC
Luliconazole inhibits ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Ergosterol is a component of the fungal cell membrane & disruption of its production can alter fluidity and integrity of the cell membrane and cell wall

Tinea pedis: apply a thin layer of cream to the affected and surrounding areas, once daily for 2 weeks.
Tinea cruris & Tinea corporis: apply topically to the affected area once daily for 1 week.

Application site reactions
Contact dermatitis
Cellulitis

For topical use only; not for ophthalmic or intravaginal administration.
May inhibit CYP2C19 and CYP3A4 isoenzymes; particularly when treating large surface areas (i.e. moderate to severe tinea cruris) that result in increased luliconazole systemic exposure.